4 documents found, page 1 of 1
Transmural Remission Improves Clinical Outcomes Up to 5 years in Crohn's Disease
Raimundo Fernandes, S; Serrazina, J; Ayala Botto, I; Leal, T; Guimarães, A; Lemos Garcia, J; Rosa, I; Prata, R; Carvalho, D; Neves, J; Campelo, PIntroduction: Evidence supporting transmural remission (TR) as a long-term treatment target in Crohn's disease (CD) is still unavailable. Less stringent but more reachable targets such as isolated endoscopic (IER) or radiologic remission (IRR) may also be acceptable options in the long-term. Methods: Multicenter retrospective study including 404 CD patients evaluated by magnetic resonance enterography and colon...
MIRRAGGE – Minimum Information Required for Reproducible AGGregation Experiments
Martins, PM; Navarro, S; Silva, A; Pinto, M; Sárkány, Z; Figueiredo, F; Pereira, PJB; Pinheiro, F; Bednarikova, Z; Burdukiewicz, M; Galzitskaya, OVReports on phase separation and amyloid formation for multiple proteins and aggregation-prone peptides are recurrently used to explore the molecular mechanisms associated with several human diseases. The information conveyed by these reports can be used directly in translational investigation, e.g., for the design of better drug screening strategies, or be compiled in databases for benchmarking novel aggregatio...
DisProt: Intrinsic protein disorder annotation in 2020
Hatos, A; Hajdu-Soltész, B; Monzon, AM; Palopoli, N; Álvarez, L; Aykac-Fas, B; Bassot, C; Benítez, GI; Bevilacqua, M; Chasapi, A; Chemes, L; Davey, NEThe Database of Protein Disorder (DisProt, URL: https://disprot.org) provides manually curated annotations of intrinsically disordered proteins from the literature. Here we report recent developments with DisProt (version 8), including the doubling of protein entries, a new disorder ontology, improvements of the annotation format and a completely new website. The website includes a redesigned graphical interfac...
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis ...
Sant'Anna, R; Gallego, P; Robinson, L; Pereira-Henriques, A; Ferreira, N; Pinheiro, F; Esperante, S; Pallares, I; Huertas, O; Almeida, M; Reixach, NTransthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson's disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes...